Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 through 69 years of age, inclusive~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months~* Active chronic HBV infection with all the following:~  1. Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not more than 96 weeks)~ 2. HBeAg positive or negative at screening~ 3. Plasma HBV DNA \>/= 1000 copies/mL at screening (irrespective of HBeAg status)~ 4. Serum ALT less than 10 times the upper limit of normal (ULN)~ 5. Calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault formula~ 6. Hemoglobin at least 8 g/dL~ 7. Neutrophils at least 1,000 /mm3~* Nucleoside naive except for lamivudine (\>/= 12 weeks of therapy)~* Negative serum beta human chorionic gonadotropin~* Compliant with adefovir dipivoxil~* Willing and able to provide written informed consent~Exclusion Criteria:~* Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study~* Male or females of reproductive potential who are unwilling to use an effective method of contraceptive while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used~* Decompensated liver disease defined as conjugated bilirubin greater than 1.5 times ULN, prothrombin time (PT) greater than 1.5 times ULN, platelets less than 75,000/mm3, serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)~* Prior use of tenofovir DF or entecavir~* Received treatment with interferon or pegylated interferon within 6 months of the screening visit~* Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater than 50 ng/mL or by any other standard of care measure.~* Co-infection with HCV (based on serology), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)~* Significant renal, cardiovascular, pulmonary, or neurological disease.~* Received solid organ or bone marrow transplantation.~* Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion~* Has proximal tubulopathy~* Known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TDF
- 2 (Type: EXPERIMENTAL): FTC/TDF

Based on this trial design, predict the completion outcome and termination type (if applicable).